Results 171 to 180 of about 95,573 (296)

Approach for reclassification of collecting duct carcinoma and comparative histopathological analysis with SMARCB1/INI1-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma.

Human Pathology, 2022
Daisuke Kiyozawa, Kenichi Kohashi, Dai Takamatsu, Takeshi Iwasaki, Daiki Shibata, Takumi Tomonaga, Y. Tateishi, M. Eto, M. Kinjo, K. Nishiyama, K. Taguchi, Y. Oshiro, Yusuke Kuboyama, M. Furuya, Y. Oda   +14 more
semanticscholar   +1 more source

Erythrocyte Antibodies in AIDS are associated with mycobacteriosis and hypergammaglobulinemia [PDF]

, 1990
A. Matuschke, AP Rapoport, B. Gathof, B. Heinrich, F. -D. Goebel, FJ Raal, J Lelie van der, J. R. Bogner, L Morris, LI Zon, LI Zon, M Adams, MH McGinniss, P Zauber, PT Toy, PT Toy, PY Lepennec, R Perricone, U. Bäcker, V Daniel, Y Inada, Y Schoenfeld   +21 more
core   +1 more source

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

International Journal of Cancer, EarlyView.
What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel, Linus Materna, Ramona Stelmach, Stefanie Zschäbitz, Stephanie Neuberger, Can D. Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff, Marit Ahrens, Pia Paffenholz, Richard Cathomas, Berna C. Özdemir, Christopher Gossler, Philipp Ivanyi, Marc Rehlinghaus, Thomas Hilser, Viktor Grünwald, Katrin Schlack   +21 more
wiley   +1 more source

Good response with nivolumab and cabozantinib combination therapy in patients with metastatic collecting duct carcinoma with high expression of PD-L1, c-MET, and AXL. [PDF]

CEN Case Rep
Umemoto T, Hasegawa M, Naruse J, Kano T, Nakajima N, Nitta M, Kawamura Y, Kajiwara H, Shoji S.   +8 more
europepmc   +1 more source

Spongiosolysis [PDF]

, 1987
Gilbert, P., Stief, Christian Georg
core   +1 more source

Quality‐adjusted life years in the presence and absence of organized mammographic screening using data from BreastScreen Norway

International Journal of Cancer, EarlyView.
What's New? Although mammographic screening can reduce breast cancer mortality and extend life, some studies have found a negative impact on net quality‐adjusted life years (QALYs). Here, the authors estimated net QALYs associated with biennial mammographic screening for women aged 50–69 years in Norway under various scenarios.
Rick Groeneweg, Nicolien T. van Ravesteyn, Lindy M. Kregting, Giske Ursin, Solveig Hofvind, Nataliia Moshina   +5 more
wiley   +1 more source

Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan. [PDF]

BMC Cancer
Kandori S, Suzuki S, Kojo K, Isoda B, Tanaka T, Nitta S, Shiga M, Nagumo Y, Ikeda A, Kawahara T, Hoshi A, Negoro H, Mathis BJ, Okuyama A, Nishiyama H.   +14 more
europepmc   +1 more source

Breast cancer incidence and survival by subtype, stage at diagnosis and socioeconomic deprivation among young women in the Community of Madrid, Spain

International Journal of Cancer, EarlyView.
What's New? Breast cancer comprises a heterogeneous group of diseases with differing features and survival outcomes. In particular, survival is affected by socioeconomic status, though age‐specific patterns remain unknown. Here, the authors examined differences in breast cancer incidence and survival specifically among young women in the Community of ...
Candela Pino‐Rosón, Sonia Ávila‐Arroyo, David Parra‐Blázquez, María J. Soto Zabalgogeazcoa, Daniel Moñino, Raquel López‐González, Clotilde Sevilla‐Hernández, Cristina González‐Blázquez, Miguel Martín, Nuria Aragonés   +9 more
wiley   +1 more source

Challenges in the future of cancer screening

International Journal of Cancer, EarlyView.
Abstract The purpose of cancer screening is to reduce mortality, and ideally incidence, from the cancer screened for. Until recently, cancer screening has been offered to all persons in pre‐defined sex‐ and age‐groups. The exception is lung screening which is targeted to high‐risk individuals.
Elsebeth Lynge, Berit Andersen, Stig E. Bojesen, Lone Kjeld Petersen, Mickael Bech, Martin Bøgsted, Mie Seest Dam, Søren Egstrand, Anne Mette Fløe Hvass, Camilla J. Kobylecki, Kristina Lång, Mads Nielsen, Giorgi Paolo Rossi, Michael Stenger, Ilse Vejborg, Future of Cancer Screening Working Group, Vibe Munk Bertelsen, Janne Bigaard, Karen Omann Binderup, Lennart Friis‐Hansen, Stine Bisgaard Greve, Jessica Xin Hjaltelin, Rikke Hedegaard Jensen, Gitte Jessing, Pia Kirkegaard, Mette Hartmann Nonboe, Tina Bech Olesen, Katrine Stolberg, Signe Bülow Therkildsen, Mette Kielsholm Thomsen   +29 more
wiley   +1 more source

Metabolic parameters analysis of ¹⁸F-FDG PET/CT in the diagnosis and differential diagnosis of collecting duct carcinoma. [PDF]

Am J Nucl Med Mol Imaging
Qiu Y, Zhang X, Cheng J, Huang W, Chen Z, Song L, Yang Q, Sun X, Wang A, Wang T, Kang L.   +10 more
europepmc   +1 more source